{"Symbol": "AGIO", "AssetType": "Common Stock", "Name": "Agios Pharm", "Description": "Agios Pharmaceuticals, Inc., a biopharmaceutical company, is dedicated to drug discovery and development in the field of cellular metabolism and adjacent areas of biology. The company is headquartered in Cambridge, Massachusetts.", "CIK": "1439222", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "88 SIDNEY STREET, CAMBRIDGE, MA, UNITED STATES, 02139", "OfficialSite": "https://www.agios.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-12-31", "MarketCapitalization": "1638237000", "EBITDA": "-466955008", "PERatio": "None", "PEGRatio": "0", "BookValue": "20.41", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-7.12", "RevenuePerShareTTM": "0.932", "ProfitMargin": "0", "OperatingMarginTTM": "-6.09", "ReturnOnAssetsTTM": "-0.199", "ReturnOnEquityTTM": "-0.302", "RevenueTTM": "54028000", "GrossProfitTTM": "-291852000", "DilutedEPSTTM": "-7.12", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0.861", "AnalystTargetPrice": "38.12", "AnalystRatingStrongBuy": "0", "AnalystRatingBuy": "7", "AnalystRatingHold": "3", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "-", "ForwardPE": "2.466", "PriceToSalesRatioTTM": "30.32", "PriceToBookRatio": "1.372", "EVToRevenue": "15.23", "EVToEBITDA": "-2.328", "Beta": "0.913", "52WeekHigh": "46", "52WeekLow": "22.24", "50DayMovingAverage": "27.38", "200DayMovingAverage": "34.08", "SharesOutstanding": "58592000", "SharesFloat": "52384000", "PercentInsiders": "1.731", "PercentInstitutions": "106.631", "DividendDate": "None", "ExDividendDate": "None"}